Month: February 2024

ZUG, Switzerland , Feb. 16, 2024 (GLOBE NEWSWIRE) — Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin B2 receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks, today announced the extraordinary general meeting of shareholders will take place on Wednesday, March 6, 2024, at 12:00 CST (6:00 a.m. EST). All relevant documents and information relating to the extraordinary general meeting, including the notice and agenda for the extraordinary general meeting, are or will be made available in the “Investors” section of Pharvaris’ website under “Events & Presentations”. The documents will also be made available on the SEC’s website at www.sec.gov. Shareholders who wish to attend the meeting should register as described in the notice and agenda for the extraordinary general...

Baltic Horizon Fund invites unitholders, investors, analysts and other stakeholders to join its investor conference webinar, scheduled on 22 February 2024 at 13:00 PM (CET) or 14:00 PM (EET). The webinar will be hosted by Tarmo Karotam, the Fund Manager of Baltic Horizon Fund. Q&A session will follow after the presentation. Due to limited webinar time, we encourage participants to send their questions no later than one day before the webinar to tarmo.karotam@nh-cap.com. To join the webinar, please register via the following link:  https://nasdaq.zoom.us/webinar/register/WN_9e5-wNgNQqS6IWUZcs-NHw You will be provided with the webinar link and instructions how to join successfully. When joining the webinar for the first time, you will be asked to download the plug-in which will take only few seconds. In case plug-in can’t be downloaded,...

Baltic Horizon Fund invites unitholders, investors, analysts and other stakeholders to join its investor conference webinar, scheduled on 22 February 2024 at 13:00 PM (CET) or 14:00 PM (EET). The webinar will be hosted by Tarmo Karotam, the Fund Manager of Baltic Horizon Fund. Q&A session will follow after the presentation. Due to limited webinar time, we encourage participants to send their questions no later than one day before the webinar to tarmo.karotam@nh-cap.com. To join the webinar, please register via the following link:  https://nasdaq.zoom.us/webinar/register/WN_9e5-wNgNQqS6IWUZcs-NHw You will be provided with the webinar link and instructions how to join successfully. When joining the webinar for the first time, you will be asked to download the plug-in which will take only few seconds. In case plug-in can’t be downloaded,...

The Board of Directors of Vistin Pharma ASA plans to propose to distribute a cash dividend of total NOK 1.00 per share, to be paid partly in June and November, for the accounting year of 2023. The formal decision regarding the dividend will be made on the company’s Annual General Meeting, which will be held on 23 May 2024. Dividend amount (per share): NOK 0.50 Declared currency: NOK Last day including right: 4 June 2024 Ex-date: 5 June 2024 Record date: 6 June 2024 Payment date (on or about): 18 June 2024 Date of approval: 23 May 2024Dividend amount (per share): NOK 0.50 Declared currency: NOK Last day including right: 5 November 2024 Ex-date: 6 November 2024 Record date: 7 November 2024 Payment date (on or about): 19 November 2024 Date of approval: 23 May 2024This information is subject to the disclosure requirements pursuant...

Volta Finance Limited (VTA / VTAS) – January 2024 monthly report NOT FOR RELEASE, DISTRIBUTION, OR PUBLICATION, IN WHOLE OR PART, IN OR INTO THE UNITED STATES ***** Guernsey, February 16th, 2024 AXA IM has published the Volta Finance Limited (the “Company” or “Volta Finance” or “Volta”) monthly report for January 2024. The full report is attached to this release and will be available on Volta’s website shortly (www.voltafinance.com). PERFORMANCE and PORTFOLIO ACTIVITY Volta Finance started the year on a positive note as the fund achieved a performance of +2.8% in January 2024. This was the extension of Volta’s strong momentum as the fund recorded its seventh positive month in a row. The performance since July-end 2023 consequently reached double digits, at +11.1%. CLOs delivered solid returns in January and outperformed traditional credit...

SABUGO, Portugal, Feb. 16, 2024 (GLOBE NEWSWIRE) — Fusion Fuel (NASDAQ: HTOO) (the “Company”) is pleased to announce that it has received notification from the European Commission that the Company’s HEVO-Portugal project was among 33 selected for approval under the Important Projects of Common European Interest (“IPCEI”) Hy2Infra program. The €650 million, 630 MW project is to be developed in Sines, Portugal, and would produce 62,000 tonnes of green hydrogen per annum. A portion of the green hydrogen is expected to be used in the production of green ammonia and exported from the Port of Sines to the Port of Rotterdam in the Netherlands. The balance would be consumed by industrial customers in the domestic Portuguese market. The IPCEI approval positions Fusion Fuel and its partners to commence funding negotiations with the relevant...

Company further establishes itself as the dominant consumer finance platform in Southeast Asia SINGAPORE, Feb. 16, 2024 (GLOBE NEWSWIRE) — MoneyHero Limited (Nasdaq: MNY) (“MoneyHero” or the “Company”), a market-leading personal finance aggregation and comparison platform in Greater Southeast Asia, today reported that, based on a preliminary and unaudited review, the Company anticipates year-over-year revenue growth of at least 60% in Singapore and 50% in Hong Kong for the month of January 2024. This growth has continued to dramatically outpace competition and further establishes MoneyHero as the dominant consumer finance platform in Southeast Asia. “Our strategy continues to show significant results, our revenue pool is expanding at an accelerated rate, and our competition has never been under more pressure,” said Prashant Aggarwal,...